http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1709041-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0a9e6421e9257148abad101e1ce6c162 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D277-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-426 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D277-48 |
| filingDate | 2005-01-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7fad041d14e13bfed4cec1d27b9de420 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_435805150990f01633930b7978af0ff0 |
| publicationDate | 2006-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-1709041-A1 |
| titleOfInvention | Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics |
| abstract | The invention relates to a compound having general formula (I), wherein: R1 represents either an optionally-substituted C1-6 alkyl or a C3-7 cycloalkyl, a thiophene, a benzothiophene, a pyridinyl, a furanyl or a phenyl which is optionally substituted; R2 and R'2 represent, independently of each other, a hydrogen atom, a halogen atom, a hydroxy, a C1-3 alkoxy, a C1-3 alkyl, a C3-7 cycloalkyl, a O-C(O)-C1-6 alkyl group, or R2 and R'2 together form an oxo group; R3 represents a hydrogen atom, a C1-6 alkyl which is optionally substituted by a hydroxy, a C1-6 cycloalkyl or a C1-3 alkoxy; either R4 or R5 represents a group (Z) and either R4 or R5 represents a -C(X)R6 group; G represents a single bond or a -CH2- group; Y represents a single bond, an oxygen atom, a sulphur atom, an optionally-substituted C1-4 alkylene group or -N(W)-; A and B represent, independently of each other, a hydrogen atom, a halogen atom, a hydroxy group, C1-3 alkyl, C1-3 alkoxy, trifluoromethyl, trifluoromethoxy or -O-CHF2; X represents O or S; R6 represents an optionally-substituted C1-6 alkoxy group, hydroxy or -NR7R8; and R7 and R8 represent, independently of each other, either a hydrogen atom, an optionally-substituted C1-6 alkyl group, an optionally-substituted C3-7 cycloalkyl group, C1-6 alkoxy or phenyl which is optionally substituted, or R7 and R8, together with the nitrogen atom bearing same, form an aziridine, azetidine, pyrrolidine, piperidine, morpholine or benzopiperidine ring. The inventive compound takes the form of a base, an acid addition salt or a hydrate. The invention also relates to the use of said compound in therapeutics |
| priorityDate | 2004-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 165.